Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
grade A 9.29 4.50% 0.40
ADVM closed down 1.77 percent on Monday, May 20, 2019, on 2.72 times normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ADVM trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 4.50%
New 52 Week High Strength 4.50%
Parabolic Rise Strength 4.50%
Stochastic Reached Overbought Strength 4.50%
Upper Bollinger Band Walk Strength 4.50%
Wide Bands Range Expansion 4.50%
Above Upper BB Strength 4.50%
Overbought Stochastic Strength 4.50%
New 52 Week Closing High Bullish 2.65%
Pocket Pivot Bullish Swing Setup 2.65%

Older signals for ADVM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Disease Gene Therapy Macular Degeneration Wet Age Related Macular Degeneration Gene Therapy Products Adverum Biotechnologies Gene Therapy Of The Human Retina Rare Genetic Disease Retinoschisis
Is ADVM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.45
52 Week Low 2.62
Average Volume 533,998
200-Day Moving Average 4.8177
50-Day Moving Average 6.051
20-Day Moving Average 6.8835
10-Day Moving Average 7.158
Average True Range 0.5535
ADX 23.83
+DI 43.5455
-DI 11.5021
Chandelier Exit (Long, 3 ATRs ) 7.789499999999999
Chandelier Exit (Short, 3 ATRs ) 7.2605
Upper Bollinger Band 8.4524
Lower Bollinger Band 5.3146
Percent B (%b) 1.14
BandWidth 45.584368
MACD Line 0.6034
MACD Signal Line 0.391
MACD Histogram 0.2124
Fundamentals Value
Market Cap 384.83 Million
Num Shares 43.3 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -5.85
Price-to-Sales 75.42
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.00
Resistance 3 (R3) 10.06 9.76 9.82
Resistance 2 (R2) 9.76 9.47 9.73 9.75
Resistance 1 (R1) 9.32 9.30 9.54 9.26 9.69
Pivot Point 9.02 9.02 9.13 8.99 9.02
Support 1 (S1) 8.58 8.73 8.80 8.52 8.09
Support 2 (S2) 8.28 8.56 8.25 8.03
Support 3 (S3) 7.84 8.28 7.97
Support 4 (S4) 7.78